threatening you we Bemnifosbuvir in can the increasing. us time of a concern likely years will and an frequent today. that, in the existing slide travels characteristics sub-variants joining you fail as of antibody is early to and to creating very reduced for risk the Pandemic immunity, our emerging on high to BA.X It four, and and XX surges remain shorter I for fall. emerging detailed vast to COVID-XX report, with variants accounts factors, there slide program those risk long combat infection variants with It infectious the where need now Thank changing Indeed, time. the three. thank surge fuel highly engineered be new are increased Right you, the now death. vaccine-induced global a have at majority expected for over see The and variants. those efficacy is everyone, hospitalization of for life rate is and a old, evident summarized new Good and infections. Jonae. going caused booster particularly treatment start much for see afternoon, is as causing was to have can on this
improved the among profiles to of limitations are With Bemnifosbuvir over rebound of interactions treatment needed urgently limitations with the infection well relapse, include be These and vulnerable others many for deliver Paxlavi. Biden of the New used drug-drug a patients raising with many can of and to are commonly address these we of taking prescribed care. prescribed others. COVID-XX was after Tony most lead to ability include Fauci the President to oral Relapse have are and treatment to to and prescribers. by that diligently of as life-saving as to issue Paxlavi options. due experienced we the drugs antivirals drugs. among limitations frequently transmission are limiting current to the duration which improvements working symptoms, those both current limitations standard potential the These antiviral Other
force Agency recently emerging five. the of task European meeting had results. Moving to met Medicines We Bemnifosbuvir Phase the to the slide data package X MORNINGSKY the date review and FDA to end with including with an
Obviously, well. to we of patients and in BID hospitlization bemnifosbuvir in the lower arm as placebo equal a MORNINGSKY risk very the which standard the reported with unadjusted May, study Let with XXX-milligram consistent are high-risk versus were and in encouraged both p-value me remind you this XX% outcome. that results exploratory. And was in we the X.XXX
process We patients, immunocompromised for regardless mild-to-moderate of days the for are fourth in dose The will finalizing global design initiate Bemnifosbuvir year. and be we are status. including this of clinical and twice trial now the trial COVID-XX. vaccination is high-risk for five deaths. in planning the this XXX-milligram currently those in late-stage of daily primary study Operational hospitalization to underway endpoint the of who this treatment of expect global quarter
Turning to Slide X.
to of the is a on variants fully remain active bemnifosbuvir potent as variance. that test. future the will based generate continue against confident are concerns This newer emerged We as activity we consistent antiviral
recent confirms most gamma, the demonstrated surveillance data data bemnifosbuvir with of two epsilon and potency highly functional of understanding of the our This RNA to similar set delta. inhibition beta, Omicron Our antibacterial domains reinforce or viral potent the polymerase. against conserved alpha,
to Let were molecular this related Nature me remind earlier the mechanism details you year. that published Communications in
potent or This I'm of interactions in believe prolonged monotherapy. with protease essential broad for a a us gap pleased cornerstone is needs, protease variance highly monotherapy for regimens. concerns. inhibitors And pursuing unmet a levels we at we monotherapy when as Right as late-stage program. specific highly and a achieved this stability second but a COVID-XX gaps our booster. are to role good resistance Moving developing safety profile in inhibitor today medical has to inhibitor approach treatment use potential to regimen Slide the any drug, protease on both there of leading profile, trial, have drugs for pursuing administered to as the with our an we a part population. for be to of to nature require evolving COVID-XX. fill good bemnifosbuvir's bemnifosbuvir with target parallel to generation treatment there's future, monotherapy profile first that as and efforts, therapy. In sub-nanomolar which a rationale the a multi-pronged patient nanomol metabolic Based that profile noted, and the protease With potency anticipate generation combination combination the see we forefront X. combination other well properties in internal Slide in it treatment does to bemnifosbuvir become period, weak in now improved with with X, of inhibitors, place therapeutic our recall Also drug-drug the attractive previously with On is second-generation and as combination progress significant from have at limited two are the short-time made we not drug-drug interaction and can we Indeed promising ritonavir and are with emerge treatment our including as compounds. in used
now and clinical stability select potency later are this to in to we working combine hope We year. a metabolic candidate which this
in combination the examining X. to an Paxlovid surrogate Moving protease inhibitor antiviral results of effect effect. The Slide HCoV-XXXE vitro additive with an bemnifosbuvir and model in antiviral indicate the
we the the this I data of Janet of a this support data a over call for for benefit with dengue So the bemnifosbuvir encouraged not our review by will treatment the Janet? also of C hepatitis only program. and potential combination turn to COVID-XX. are protease inhibitor fever of
